Siga Technologies has won US approval for Tpoxx, the first drug to be licensed to treat smallpox which, despite being eradicated in the 1980s, might be still used in a bioattack.
The FDA has approved Genentech’s Rituxan (rituximab) for use in adults with moderate-to-severe pemphigus vulgaris (PV), making it the first treatment for the condition in more than 60 years.